Fireman B.V. (IFRX) Stock Price, Quote & News

Company Profile

InflaRx N.V., a clinical-stage biopharmaceutical company, discovers and develops inhibitors using C5a technology in Germany and the United States. The company's C5a is an inflammatory mediator to treat variety of autoimmune and other inflammatory diseases. Its lead product candidate is vilobelimab, a a first-in-class monoclonal anti-human complement factor C5a antibody, which is in Phase 3 clinical trial for the treatment for patients suffering from early septic organ dysfunction, biological pro...

Industry: Biotechnology

Sector: Healthcare

Phone: 49 3641 508 180

Website: www.inflarx.de

Address:

Winzerlaer Str. 2, Jena, Germany

Barkingdogs May. 13 at 11:58 AM

$IFRX

0 · Reply

Barkingdogs May. 13 at 11:55 AM

$IFRX

0 · Reply

GoCoogs May. 13 at 11:54 AM

$IFRX IFRX InflaRx upgraded to Strong Buy from Outperform at Raymond James; tgt $9 (2.43)

0 · Reply

EdV3 May. 13 at 11:45 AM

$IFRX https://www.streetinsider.com/dr/news.php?id=26481611&gfv=1 Can't see behind paywall but looks like rj upgraded and raised pt?

0 · Reply

Yoyo35 May. 13 at 11:43 AM

$IFRX where ?🙂

0 · Reply

Barkingdogs May. 13 at 11:41 AM

$IFRX buy buy buy before bye bye

0 · Reply

Barkingdogs May. 13 at 11:32 AM

$IFRX bow wow 🤑🤑🤑🤑🤑

0 · Reply

Barkingdogs May. 13 at 11:32 AM

$IFRX TCG Crossover reports ownership 14,500,000 shares

0 · Reply

robertartur May. 13 at 10:12 AM

$IFRX My broker reports that Inflarx will release its quarterly results shortly (maybe today).

1 · Reply

Dave1961 May. 13 at 5:22 AM

$IFRX Our day is coming soon!!

0 · Reply

InflaRx price target raised to $8 from $6 at H.C. Wainwright

May 8, 2026, 8:30 AM EDT - 5 days ago

InflaRx Transcript: Investor update

May 8, 2026, 8:15 AM EDT - 5 days ago

InflaRx Announces Closing of $150 Million Underwritten Offering of Ordinary Shares

2026-05-07T03:51:29.000Z - 6 days ago

InflaRx to develop izicopan in AAV

May 6, 2026, 8:30 AM EDT - 7 days ago

InflaRx Announces Pricing of $150 Million Underwritten Offering of Ordinary Shares

May 6, 2026, 8:25 AM EDT - 7 days ago

InflaRx Announces Advancement of Izicopan in ANCA-Associated Vasculitis and Select Renal Diseases

2026-05-04T12:09:26.000Z - 9 days ago

InflaRx announces new izicopan pre-clinical data

May 4, 2026, 7:30 AM EDT - 9 days ago

InflaRx Reports Favorable Reactive Metabolite Profile for Izicopan in Human Liver Microsomes

May 1, 2026, 7:30 AM EDT - 12 days ago

InflaRx to Report First Quarter 2026 Results on May 7, 2026

Apr 28, 2026, 7:30 AM EDT - 15 days ago

InflaRx Regains Compliance with Nasdaq Minimum Bid Price Requirement

2026-04-24T11:41:38.000Z - 19 days ago

InflaRx assumed with an Outperform at Oppenheimer

2026-04-09T11:54:44.000Z - 4 weeks ago

InflaRx announces new izicopan in vitro findings

Apr 9, 2026, 7:30 AM EDT - 4 weeks ago

InflaRx Reports New Mechanistic Data for Izicopan Supporting its Potential as a Best-in-Class C5aR Inhibitor

Mar 31, 2026, 7:30 AM EDT - 6 weeks ago

InflaRx Announces Participation in the Raymond James 2026 Biotech Innovation Symposium

2026-03-30T12:10:23.000Z - 6 weeks ago

InflaRx presents vilobelimab data

Mar 30, 2026, 7:30 AM EDT - 6 weeks ago

InflaRx Highlights Clinical Activity of Vilobelimab in Pyoderma Gangrenosum in Late-Breaker Oral Presentation at 2026 American Academy of Dermatology Annual Meeting

2026-03-20T11:20:14.000Z - 7 weeks ago

InflaRx price target lowered to $14 from $22 at Guggenheim

2026-03-19T11:35:54.000Z - 7 weeks ago

InflaRx reports FY25 EPS (EUR 0.68) vs. (EUR 0.78) last year

Mar 19, 2026, 7:30 AM EDT - 7 weeks ago

InflaRx Reports Full Year 2025 Results and Highlights Key Achievements and Expected Milestones

Mar 18, 2026, 7:30 AM EDT - 2 months ago

InflaRx Announces Late-Breaker Oral Presentation on Vilobelimab Phase 3 Results in Pyoderma Gangrenosum at 2026 American Academy of Dermatology Annual Meeting

Mar 13, 2026, 5:00 PM EDT - 2 months ago

InflaRx Announces Receipt of Nasdaq Deficiency Notice Regarding Minimum Bid Price Requirement

Mar 12, 2026, 7:30 AM EDT - 2 months ago

InflaRx to Report Full Year 2025 Results on March 19, 2026

Mar 9, 2026, 9:20 AM EDT - 2 months ago

InflaRx Transcript: Leerink Global Healthcare Conference 2026

Feb 26, 2026, 7:30 AM EST - 2 months ago

InflaRx Announces Participation in the Leerink Partners Global Healthcare Conference

Feb 25, 2026, 8:40 AM EST - 2 months ago

InflaRx Transcript: Oppenheimer 36th Annual Healthcare Life Sciences Conference

Feb 11, 2026, 11:30 AM EST - 3 months ago

InflaRx Transcript: Guggenheim Securities Emerging Outlook: Biotech Summit 2026

Jan 29, 2026, 7:30 AM EST - 3 months ago

InflaRx Announces Participation in February Investor Conferences

2026-01-08T13:21:00.000Z - 4 months ago

InflaRx to prioritize izicopan as lead asset, reduces workforce by 30%

Jan 8, 2026, 8:00 AM EST - 4 months ago

InflaRx Announces Strategy Focused on Capital-Efficient Execution with Izicopan and Near-Term Value Creation

2025-12-30T12:40:39.000Z - 4 months ago

InflaRx outlines data analyses of Phase 3 study for vilobelimab in PG

Dec 30, 2025, 7:30 AM EST - 4 months ago

InflaRx Provides Update on Phase 3 Data Analyses for Vilobelimab in Pyoderma Gangrenosum

2025-12-11T12:35:44.000Z - 5 months ago

InflaRx announces international nonproprietary name of “izicopan” for INF904

Dec 11, 2025, 7:30 AM EST - 5 months ago

InflaRx Announces International Nonproprietary Name of “Izicopan” for INF904

2025-12-03T11:53:16.000Z - 5 months ago

InflaRx downgraded to Market Perform from Outperform at Leerink

2025-12-03T11:16:16.000Z - 5 months ago

InflaRx downgraded to Market Perform from Outperform at Leerink

2025-11-14T13:45:17.000Z - 6 months ago

Largest borrow rate increases among liquid names

GETY HPK JDST SGML UPXI

Nov 11, 2025, 2:30 PM EST - 6 months ago

InflaRx Transcript: Guggenheim Securities 2nd Annual Healthcare Innovation Conference

2025-11-11T11:20:32.000Z - 6 months ago

InflaRx price target raised to $8 from $3 at Cantor Fitzgerald

2025-11-11T11:16:27.000Z - 6 months ago

InflaRx price target raised to $9 from $2 at Raymond James

2025-11-11T11:15:24.000Z - 6 months ago

InflaRx price target raised to $7 from $3 at Oppenheimer

2025-11-10T21:11:57.000Z - 6 months ago

InflaRx price target raised to $24 from $3 at Lucid Capital

2025-11-10T13:20:47.000Z - 6 months ago

InflaRx price target raised to $22 from $10 at Guggenheim

Nov 10, 2025, 8:00 AM EST - 6 months ago

InflaRx Transcript: Status Update

Nov 10, 2025, 7:30 AM EST - 6 months ago

InflaRx Reports Positive Phase 2a Data for INF904 in Hidradenitis Suppurative (HS) and Chronic Spontaneous Urticaria (CSU)

Nov 7, 2025, 4:05 PM EST - 6 months ago

InflaRx to Announce Topline Data from Phase 2a Clinical Trial of INF904 in Hidradenitis Suppurativa and Chronic Spontaneous Urticaria

Oct 21, 2025, 7:20 AM EDT - 7 months ago

InflaRx Announces Participation in the Guggenheim Securities 2nd Annual Healthcare Innovation Conference

Sep 4, 2025, 9:10 AM EDT - 8 months ago

InflaRx Transcript: Cantor Global Healthcare Conference 2025

Aug 21, 2025, 7:30 AM EDT - 9 months ago

InflaRx Announces Participation in September Investor Conferences

Aug 7, 2025, 7:30 AM EDT - 9 months ago

InflaRx Reports Second Quarter 2025 Financial Results and Provides Business Update

Jul 31, 2025, 7:30 AM EDT - 10 months ago

InflaRx to Report Second Quarter 2025 Results on August 7, 2025

Jun 4, 2025, 7:35 AM EDT - 1 year ago

InflaRx Transcript: Jefferies Global Healthcare Conference 2025

May 28, 2025, 1:30 AM EDT - 1 year ago

InflaRx Announces Outcome of Interim Analysis for Vilobelimab Phase 3 Trial in Pyoderma Gangrenosum

May 22, 2025, 7:30 AM EDT - 1 year ago

InflaRx to Participate in Upcoming Investor Conferences

May 7, 2025, 7:30 AM EDT - 1 year ago

InflaRx Reports First Quarter 2025 Financial Results and Provides Business Update

Apr 30, 2025, 7:30 AM EDT - 1 year ago

InflaRx to Report First Quarter 2025 Results on May 7, 2025

Mar 20, 2025, 7:30 AM EDT - 1 year ago

InflaRx Reports Full Year 2024 Results and Highlights Key Achievements and Expected Milestones

Mar 7, 2025, 8:00 AM EST - 1 year ago

InflaRx Showcases Vilobelimab's Role in Immuno-Dermatology at the 2025 AAD Annual Meeting

Feb 28, 2025, 9:00 AM EST - 1 year ago

InflaRx to Showcase Vilobelimab's Role in Immuno-Dermatology at the 2025 AAD Annual Meeting

Feb 25, 2025, 7:30 AM EST - 1 year ago

InflaRx to Report Full Year 2024 Results on March 20 and Announces Participation in March Investor Conferences

Feb 18, 2025, 4:01 PM EST - 1 year ago

InflaRx Announces Closing of $30 Million Public Offering of Ordinary Shares and Pre-Funded Warrants

Feb 13, 2025, 9:45 PM EST - 1 year ago

InflaRx Announces Pricing of $30 Million Public Offering of Ordinary Shares and Pre-Funded Warrants

Feb 13, 2025, 4:01 PM EST - 1 year ago

InflaRx Announces Public Offering of Ordinary Shares and Pre-Funded Warrants

Jan 23, 2025, 7:30 AM EST - 1 year ago

InflaRx Announces Participation in Guggenheim SMID Cap Biotech Conference

Jan 15, 2025, 12:30 PM EST - 1 year ago

InflaRx Receives European Commission Approval for GOHIBIC® (vilobelimab) for the Treatment of SARS-CoV-2-Induced Acute Respiratory Distress Syndrome (ARDS)

Dec 20, 2024, 7:30 AM EST - 1 year ago

InflaRx Announces First Patient Dosed in Phase 2a Study for Oral C5aR Inhibitor INF904

Dec 4, 2024, 2:30 PM EST - 1 year ago

InflaRx Transcript: Piper Sandler 36th Annual Healthcare Conference

Nov 15, 2024, 7:51 AM EST - 1 year ago

InflaRx Receives Positive CHMP Opinion for GOHIBIC® (Vilobelimab) for the Treatment of SARS-CoV-2-Induced Acute Respiratory Distress Syndrome

Nov 11, 2024, 11:00 AM EST - 1 year ago

InflaRx Transcript: Guggenheim Securities Inaugural Healthcare Innovation Conference

Nov 8, 2024, 7:30 AM EST - 1 year ago

InflaRx Reports Third Quarter 2024 Financial Results and Provides Business Update

Sep 25, 2024, 7:30 AM EDT - 1 year ago

InflaRx Presents Post Hoc Analysis of SHINE Trial of Vilobelimab in Hidradenitis Suppurativa at the 2024 European Academy of Dermatology and Venereology Congress

Sep 18, 2024, 9:45 AM EDT - 1 year ago

InflaRx Transcript: 2024 Cantor Fitzgerald Global Healthcare Conference

Sep 3, 2024, 7:30 AM EDT - 1 year ago

InflaRx Presents New Preclinical Findings for INF904 at the 19th European Meeting on Complement in Human Diseases

Aug 27, 2024, 7:30 AM EDT - 1 year ago

InflaRx Announces Participation in September Investor Events

Aug 8, 2024, 7:30 AM EDT - 1 year ago

InflaRx Reports Second Quarter 2024 Financial Results and Provides Business Update

Aug 1, 2024, 7:30 AM EDT - 1 year ago

InflaRx to Report Second Quarter 2024 Results on August 8, 2024

Jun 24, 2024, 8:02 AM EDT - 2 years ago

InflaRx's GOHIBIC (Vilobelimab) Selected for First BARDA-Sponsored Clinical Trial to Evaluate Novel Host-Directed Therapeutics for Acute Respiratory Distress Syndrome (ARDS)

Jun 5, 2024, 12:00 PM EDT - 2 years ago

InflaRx Hosts R&D Event Highlighting the Promise of INF904

May 21, 2024, 2:30 PM EDT - 2 years ago

InflaRx Presents New Analysis of PANAMO Phase III Trial in Severe COVID-19 at ATS 2024 Showing Potential Synergy With Vilobelimab When Used in Combination with Other Immunomodulators

May 8, 2024, 7:30 AM EDT - 2 years ago

InflaRx Reports First Quarter 2024 Financial Results and Provides Business Update

Apr 24, 2024, 7:30 AM EDT - 2 years ago

InflaRx to Participate in Capital One Securities 1st Annual Biotech/Biopharma Disrupters Event

Barkingdogs May. 13 at 11:58 AM

$IFRX

0 · Reply

Barkingdogs May. 13 at 11:55 AM

$IFRX

0 · Reply

GoCoogs May. 13 at 11:54 AM

$IFRX IFRX InflaRx upgraded to Strong Buy from Outperform at Raymond James; tgt $9 (2.43)

0 · Reply

EdV3 May. 13 at 11:45 AM

$IFRX https://www.streetinsider.com/dr/news.php?id=26481611&gfv=1 Can't see behind paywall but looks like rj upgraded and raised pt?

0 · Reply

Yoyo35 May. 13 at 11:43 AM

$IFRX where ?🙂

0 · Reply

Barkingdogs May. 13 at 11:41 AM

$IFRX buy buy buy before bye bye

0 · Reply

Barkingdogs May. 13 at 11:32 AM

$IFRX bow wow 🤑🤑🤑🤑🤑

0 · Reply

Barkingdogs May. 13 at 11:32 AM

$IFRX TCG Crossover reports ownership 14,500,000 shares

0 · Reply

robertartur May. 13 at 10:12 AM

$IFRX My broker reports that Inflarx will release its quarterly results shortly (maybe today).

1 · Reply

Dave1961 May. 13 at 5:22 AM

$IFRX Our day is coming soon!!

0 · Reply

cielo1 May. 13 at 2:14 AM

$IFRX anything under $10 at this juncture is noise!

0 · Reply

Holten7575 May. 13 at 1:27 AM

$IFRX $ERNA our day is coming as well

1 · Reply

EdV3 May. 13 at 1:07 AM

$IFRX 14.5m shares for tcg crossover...9.8%

1 · Reply

Holten7575 May. 12 at 7:25 PM

$IFRX did they grab your stop losses and shake the weak

2 · Reply

royalstocktrading May. 12 at 6:08 PM

$IFRX I usually don't consider technicals on micro biotech specs, but the 9ema bounce has been consistent after overbought pullbacks. Also declining sell volume. Bullish above/bearish below.

0 · Reply

EdV3 May. 12 at 5:18 PM

$IFRX I worry about those two downside gaps at 1.60 and 2.20 but the fundamentals and technicals remain hella bullish now we wait.....

1 · Reply

Yoyo35 May. 12 at 5:06 PM

$IFRX Today's red sea is a direct reaction to the 3.8% inflation data. Yields are spiking and the XBI is taking the hit as investors rotate out of high-risk growth stocks Pre-revenue biotechs are getting hit the hardest since they rely entirely on future funding and cash runways 🫩🫩🫩.

0 · Reply

otcgtc May. 12 at 3:36 PM

$IFRX ...

0 · Reply

AngelInvestor_INF May. 12 at 3:35 PM

$IFRX the stock will be drawn under 2$ by profit takers but also by shorts, poising it for a short squeeze during the next run. It's not a question of if, but of when it will run above 3$.

1 · Reply

NYBomba May. 12 at 3:07 PM

$IFRX - - MM/specialist are bringing it down to increase their inventory, they just got 150 million and its trading at 170 CAP with a potential explosive pipeline, you do the math … for those of you selling ”buh-bye”

1 · Reply

bsyd02 May. 12 at 3:02 PM

$IFRX glad I got out when I did. This companies like a drug I wanna get back in lmao

0 · Reply

levystrauss May. 12 at 2:52 PM

$IFRX che casca

2 · Reply

Market Cap	180.73M
Revenue (ttm)	30,000.00
Net Income (ttm)	-51.63M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	-172,100.01%
Debt to Equity Ratio	0.00

Volume	2,290,600
Avg Vol	1,665,308
Day's Range	N/A - N/A
Shares Out	72.29M
Stochastic %K	53%
Beta	2.42
Analysts	Strong Sell
Price Target	$8.86